# 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

> **NCT00005047** · PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 521 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** methotrexate
- **DRUG:** vinblastine

## Key facts

- **NCT ID:** NCT00005047
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1997-08
- **Primary completion:** 2011-03
- **Final completion:** 2014-12
- **Target enrollment:** 521 (ACTUAL)
- **Why stopped:** Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005047, "4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*